Johnson plans to increase investment in Ken-Ya within NT$350 million, aiming for board seats and M&A declaration
Johnson announced its plan to increase its investment in Ken-Ya, aiming to secure board seats and potentially pursue M&A, to integrate their complementary strengths in R&D, distribution, and technology. Ken-Ya also announced a stock split plan.
📋 Article Processing Timeline
- 📰 Published: April 7, 2026 at 22:04
- 🔍 Collected: April 7, 2026 at 23:00 (56 min after Published)
- 🤖 AI Analyzed: April 20, 2026 at 13:21 (302h 21m after Collected)
Johnson announced today via press release that it has accumulated a holding of 22.94% in Ken-Ya shares.
Johnson stated that this increase in shareholding, in addition to responding to Ken-Ya's announced share swap merger with i-Vee and continuing to protect its investment rights as the largest institutional shareholder, is also based on the complementarity of R&D patents, terminal distribution channels, and technology platforms, considering "resource sharing". This includes Johnson's high direct penetration rate in domestic hospitals, clinics, and chain pharmacies.
Ken-Ya possesses core competitiveness in niche new drug R&D, sustained-release formulation development, and high-quality PIC/S GMP injectable production, serving as a long-term strategic layout for Taiwan's biotechnology industry ecosystem.
Furthermore, Johnson's board of directors has resolved to amend the company's articles of incorporation, in line with practical business needs and future financing plans, without affecting shareholder rights. This includes a "one-for-two" stock split plan, adjusting the par value per share from NT$10 to NT$5. With the par value halved, the number of shares held by original shareholders will double, ensuring that the market value of existing shareholders' holdings remains unchanged. This plan is to be executed upon approval by the shareholders' meeting. (Editor: Yang Kai-Hsiang) April 7, 115 (2026)
Johnson stated that this increase in shareholding, in addition to responding to Ken-Ya's announced share swap merger with i-Vee and continuing to protect its investment rights as the largest institutional shareholder, is also based on the complementarity of R&D patents, terminal distribution channels, and technology platforms, considering "resource sharing". This includes Johnson's high direct penetration rate in domestic hospitals, clinics, and chain pharmacies.
Ken-Ya possesses core competitiveness in niche new drug R&D, sustained-release formulation development, and high-quality PIC/S GMP injectable production, serving as a long-term strategic layout for Taiwan's biotechnology industry ecosystem.
Furthermore, Johnson's board of directors has resolved to amend the company's articles of incorporation, in line with practical business needs and future financing plans, without affecting shareholder rights. This includes a "one-for-two" stock split plan, adjusting the par value per share from NT$10 to NT$5. With the par value halved, the number of shares held by original shareholders will double, ensuring that the market value of existing shareholders' holdings remains unchanged. This plan is to be executed upon approval by the shareholders' meeting. (Editor: Yang Kai-Hsiang) April 7, 115 (2026)